期刊文献+

毛细管电泳法测定小鼠组织中的反义核酸药物KS0604 被引量:1

Quantitative Determination of an Antisense Nucleic Acid Drug KS0604 in Mouse Tissues by CE
原文传递
导出
摘要 目的:建立小鼠组织中KS0604的定量分析方法。方法:采用组织消化结合基于离子交换和反相分配原理的两步固相萃取法,并采用无胶筛分毛细管电泳技术测定小鼠组织中的KS0604。结果:小鼠肾组织中KS0604在2.0~2000μg·g^(-1)范围内呈良好线性,最低定量限LOQ为2.0μg·g^(-1);其他组织中KS0604在1.3~128μg·g^(-1)范围内呈良好线性,最低定量限LOQ为1.3μg·g^(-1);r>0.999。加样回收率试验RSD<10.82%,精密度试验RSD<2.3%,稳定性试验结果表明KS0604在小鼠组织中的稳定性良好。结论:该方法可用于定量检测小鼠组织中的KS0604。 Objective:To establish a method for the quantitative determination of KS0604 in the mouse tissues.Method:A dual solid phase extraction(SPE) pretreatment method coupling with non-gel sieving capillary electrophoresis(NGCE) was established to determine the content of KS0604 in the tissues of mice.Result:The calibration curve of KS0604 was linear within the concentration range of 2.0-2 000μg ? g^(-1) in kidney and 1.3-128μg ? g^(-1) in the other mouse tissues with correlation coefficients(r) above 0.999. The LLOQ was 2.0μg ? g ^(-1) in kidney and 1.3μg ? g ^(-1) in the other mouse tissues.The RSD of the sample-adding recovery of KS0604 in mouse tissues was less than 10.82%and the precision RSD of the assay was below 2.3%.KS0604 was stable in mouse tissues. Conclusion:The combined method of solid-phase extraction and NGCE can be used in the detection and quantitative determination of KS0604 in mouse tissues.
出处 《中国药师》 CAS 2012年第5期629-632,共4页 China Pharmacist
关键词 非胶筛分毛细管电泳 反义核酸 组织 小鼠 Non-gel sieving capillary electrophoresis Antisense nucleic acid Tissue Mice
  • 相关文献

参考文献4

二级参考文献23

  • 1秦燕,陈毓芳,林峰,张美金.固相萃取-高效液相色谱法同时测定牛奶中的多种四环素残留[J].食品科学,2005,26(3):202-204. 被引量:25
  • 2刘勇,邓斌,张曦,毛华明.牛奶中6种磺胺类药物残留的HPLC分析方法研究[J].中国畜牧杂志,2006,42(1):21-23. 被引量:7
  • 3Lopes de Menezes DE,Hudon N,McIntosh N,et al.Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotides G3139 combined with free and liposomal doxorubicin [J].Clin Cancer Res,2000,6(7):2891-2902.
  • 4Geary RS,Leeds JM,Fitchett J,et al.Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor c-raf-1 kinase expression[J].Drug Metab Disp-os,1997,25(11):1272-1281.
  • 5Cossum PA,Truong L,Owens SR,et al.Pharmacokinetics of a 14 C-labeled phosphorothioate oligonculeotide,ISIS 2105,after intradermal administration to rats [J].J Pharm Exp Ther,1994,269(1):89-94.
  • 6Rafai A,Brysch W,Fadden K,et al.Clearance kinetics,biodistribution,and organ saturability of phosphorothioate oligodeoxynucleotides in mice [J].Am J Pathol,1996,149(2):717-725.
  • 7Perry CM,Barman Balfour JA.Formivirsen [J].Drugs,1999,57(3):375-380.
  • 8Agrawal S,Temsamani J,Tang JY.Pharmacokinetics,biodistribution,and stability of oligodeoxynucleotide phosphorothioates in mice [J].Proc Natl Acad Sci USA,1991,88:7595-7599.
  • 9Crook ST,Grillone LR,Tendolkar A,et al.A pharmacokinetic evaluation of 14 C-labeled afovirsen sodium in patients with genital warts [J].Clin Pharm Ther,1994,56(6,Part 1):641-646.
  • 10Sands H,Gorey-Feret LJ,Cocuzza AJ,et al.Biodistribution and metabolism of internally 3 H-labeled oligonucleotides [J].Mol Pharmacol,1994,45:932-943.

共引文献11

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部